SLC16A13 Antibody

What is SLC16A13 and why is it relevant to diabetes research?

SLC16A13 (solute carrier family 16 member 13) encodes monocarboxylate transporter 13 (MCT13), a multi-pass membrane protein that functions as a proton-linked monocarboxylate transporter. Recent genome-wide association studies have identified SLC16A13 as a susceptibility gene for type 2 diabetes, particularly in individuals of Mexican origin . The protein is predominantly expressed in the liver and duodenum, with research showing that alterations in SLC16A13 function affect fatty acid and lipid metabolism . Knockout studies in mice demonstrate that loss of Slc16a13 increases mitochondrial respiration in the liver, leading to reduced hepatic lipid accumulation and increased hepatic insulin sensitivity . These findings position SLC16A13 as a potential therapeutic target for both type 2 diabetes and non-alcoholic fatty liver disease .

What types of SLC16A13 antibodies are currently available for research?

Current research-grade SLC16A13 antibodies are predominantly rabbit polyclonal antibodies that target various epitopes of the protein. Several validated options include:

Most antibodies target the C-terminal region of SLC16A13, with applications primarily in Western blot, immunohistochemistry, and ELISA techniques .

What is the protein structure and molecular characteristics of SLC16A13?

SLC16A13 belongs to category I of the SLC16 transporter family . The protein consists of 426 amino acids with a calculated molecular weight of approximately 45 kDa, though observed weights in experimental contexts range from 40-50 kDa depending on post-translational modifications . As a multi-pass membrane protein, SLC16A13 contains several transmembrane domains (TMDs) that are characteristic of monocarboxylate transporters.

Comparative analysis of SLC16 family members has identified key transmembrane domains (TMDs 1 and 8) that play crucial roles in transport function. Three charged residues—K38 in TMD 1 and D309 and R313 in TMD 8—appear functionally important for category I transporters, with K38 and D309 being present in all category I members (including SLC16A13) but replaced by non-charged residues in category II members . This structural information is valuable when selecting antibody epitopes that won't interfere with functional domains.

How should researchers select the appropriate SLC16A13 antibody for their specific application?

Selecting the appropriate SLC16A13 antibody requires consideration of several factors:

• Experimental Application: Different applications require antibodies with specific characteristics:

  • For Western blot applications, antibodies with documented specificity at the expected molecular weight (40-50 kDa) are preferred

  • For immunohistochemistry, validated antibodies with specific tissue reactivity are essential, with antigen retrieval conditions optimized (e.g., antibody 30466-1-AP is validated with TE buffer pH 9.0 or citrate buffer pH 6.0)

  • For co-immunoprecipitation studies investigating protein interactions, antibodies targeting regions away from interaction domains are preferable

• Species Reactivity: Select antibodies validated in your experimental species. Most available antibodies react with human, mouse, and rat SLC16A13 .

• Epitope Targeting: Consider the protein region being targeted:

  • C-terminal antibodies (e.g., ABIN6256950, ABIN7185118, A26731) are useful for detecting full-length protein

  • Antibodies against specific amino acids (e.g., L423) may be valuable for detecting particular variants or splice forms

• Validation Data: Review Western blot images, IHC staining patterns, and specificity documentation. The antibody should detect endogenous SLC16A13 at the expected molecular weight in appropriate tissues, particularly liver samples .

What controls should be included when validating an SLC16A13 antibody?

Proper validation of SLC16A13 antibodies requires rigorous controls:

• Positive Tissue Controls: Include known expressing tissues such as:

  • Liver tissue (mouse, rat, human) - primary site of expression

  • Pancreatic tissue (particularly pancreatic cancer tissue for IHC)

• Negative Controls:

  • Primary antibody omission controls

  • Tissue samples from SLC16A13 knockout models (if available)

  • Tissues with minimal SLC16A13 expression

  • Pre-adsorption with immunizing peptide

• Loading Controls:

  • For Western blot, include appropriate housekeeping proteins

  • For IHC/IF, include counterstaining to visualize cellular structures

• Molecular Weight Verification:

  • Confirm detection at the expected molecular weight (40-50 kDa)

  • Be aware that glycosylation or other post-translational modifications may affect observed molecular weight

• Specificity Verification:

  • Knockdown/knockout validation

  • Overexpression validation

  • Multiple antibodies targeting different epitopes should produce consistent results

How can researchers troubleshoot non-specific binding or weak signals when using SLC16A13 antibodies?

When encountering issues with SLC16A13 antibodies:

• For Weak Signals:

  • Optimize antibody concentration based on manufacturer recommendations (e.g., WB: 1:500-1:2000, IHC: 1:50-1:500 for antibody 30466-1-AP)

  • Increase protein loading for Western blot

  • Extend primary antibody incubation time

  • Enhance detection system sensitivity

  • For IHC, optimize antigen retrieval methods (TE buffer pH 9.0 or citrate buffer pH 6.0 for some antibodies)

• For Non-specific Binding:

  • Increase blocking time/concentration

  • Use alternative blocking agents (BSA, milk, commercial blockers)

  • Increase washing duration/frequency

  • Reduce primary antibody concentration

  • Use more stringent washing conditions

  • Pre-adsorb antibody with tissues lacking SLC16A13

• For Inconsistent Results:

  • Verify protein extraction methods are compatible with membrane proteins

  • Ensure sample preparation maintains protein integrity

  • Test multiple antibodies targeting different epitopes

  • Confirm expression patterns match known tissue distribution (high in liver)

What are the optimal conditions for using SLC16A13 antibodies in Western blot applications?

For optimal Western blot detection of SLC16A13:

• Sample Preparation:

  • Use appropriate lysis buffers for membrane proteins containing detergents (e.g., RIPA buffer with 1% NP-40 or Triton X-100)

  • Include protease inhibitors to prevent degradation

  • Avoid boiling samples for extended periods as this may cause aggregation of membrane proteins

  • Load 20-40 μg of total protein per lane as demonstrated in successful blots

• Gel Electrophoresis and Transfer:

  • Use 10-12% SDS-PAGE gels for optimal separation around the 40-50 kDa range

  • Consider using wet transfer systems for efficient transfer of membrane proteins

  • Transfer to PVDF membranes which may better retain hydrophobic membrane proteins

• Blocking and Antibody Incubation:

  • Block membranes with 5% non-fat milk or BSA in TBST

  • Use antibody dilutions according to manufacturer recommendations:

    • 1:500-1:2000 for WB applications (e.g., antibody 30466-1-AP)

  • Incubate primary antibody overnight at 4°C for optimal binding

  • Use secondary antibodies at 1:5000-1:10000 dilution

• Detection:

  • Use enhanced chemiluminescence (ECL) detection systems

  • Expect bands between 40-50 kDa representing SLC16A13

  • Verify with positive control tissues such as liver samples

How should researchers optimize immunohistochemistry protocols for SLC16A13 detection?

For successful immunohistochemical detection of SLC16A13:

• Tissue Preparation:

  • Use freshly fixed tissues (10% neutral buffered formalin)

  • Paraffin embedding is suitable for most applications

  • Section thickness of 4-6 μm is recommended

• Antigen Retrieval:

  • Heat-induced epitope retrieval is essential

  • For antibody 30466-1-AP, use TE buffer pH 9.0 as the primary recommendation

  • Alternatively, citrate buffer pH 6.0 can be used as noted in product documentation

  • Microwave or pressure cooker-based retrieval for 10-20 minutes

• Blocking and Antibody Incubation:

  • Block with 5-10% normal serum from the same species as the secondary antibody

  • Use antibody dilutions according to manufacturer:

    • 1:50-1:500 for IHC applications (e.g., antibody 30466-1-AP)

  • Incubate primary antibody overnight at 4°C

  • Include positive control tissues (liver, pancreatic cancer tissue)

• Detection and Counterstaining:

  • Use polymer-based detection systems for enhanced sensitivity

  • Counterstain with hematoxylin for nuclear visualization

  • Mount with permanent mounting medium

How can SLC16A13 antibodies be used to investigate protein-protein interactions?

SLC16A13 interaction studies can be performed using:

• Co-Immunoprecipitation (Co-IP):

  • Use antibodies targeting regions away from known interaction domains

  • The C-terminal antibodies (ABIN6256950, ABIN7185118, A26731) may be suitable

  • Research has shown SLC16A11 (a related transporter) interacts with Basigin (BSG) , suggesting similar interactions may exist for SLC16A13

  • Pre-clear lysates to reduce non-specific binding

  • Use appropriate negative controls (IgG, unrelated antibodies)

  • Validate interactions with reverse Co-IP

• Proximity Ligation Assay (PLA):

  • Useful for detecting in situ protein interactions

  • Requires antibodies from different species or directly conjugated antibodies

  • Can detect native interactions in fixed cells or tissues

  • Provides spatial information about interaction sites

• Immunofluorescence Co-localization:

  • Use fluorescently-labeled secondary antibodies against SLC16A13 and potential interacting partners

  • Include appropriate controls for bleed-through and non-specific binding

  • Analyze using confocal microscopy and quantitative co-localization metrics

• FRET/BRET Analyses:

  • For live-cell interaction studies

  • Requires fusion protein constructs

  • Can provide dynamic interaction information

Since research has shown that coding variants in the related SLC16A11 affect interaction with BSG leading to reduced levels at the cell surface , similar approaches could be valuable for investigating SLC16A13 interactions.

How does SLC16A13 function contribute to metabolic disease pathophysiology?

SLC16A13's role in metabolic disease involves several mechanisms:

• Lactate Transport and Energy Metabolism:

  • SLC16A13 functions as a lactate transporter at the plasma membrane

  • By regulating lactate flux, it influences cellular energy metabolism

  • In knockout mice, loss of Slc16a13 increases mitochondrial respiration in the liver

• Hepatic Lipid Accumulation:

  • Slc16a13 knockout mice show reduced hepatic lipid accumulation when fed a high-fat diet

  • This suggests SLC16A13 activity may contribute to non-alcoholic fatty liver disease development

• Insulin Sensitivity:

  • Loss of Slc16a13 leads to increased hepatic insulin sensitivity in obese mice

  • The proposed mechanism involves reduced intrahepatocellular lactate availability driving:

    • Increased AMPK activation

    • Enhanced mitochondrial respiration

    • Reduced hepatic lipid content

    • Attenuation of hepatic diacylglycerol-PKCε mediated insulin resistance

• Genetic Association with Type 2 Diabetes:

  • Genome-wide association studies identified SLC16A13 as a susceptibility gene for type 2 diabetes

  • The T2D risk haplotype includes both coding and non-coding variants

  • These variants disrupt SLC16A13 function through two mechanisms:

    • Decreased gene expression in liver due to non-coding variants

    • Altered protein interactions due to coding variants

These findings collectively position SLC16A13 as a potential therapeutic target for both type 2 diabetes and non-alcoholic fatty liver disease .

What experimental models are available for studying SLC16A13 function in metabolic diseases?

Several experimental models are available:

• Genetic Models:

  • Slc16a13 knockout mice have been developed and characterized

  • These mice show increased mitochondrial respiration, reduced hepatic lipid accumulation, and improved insulin sensitivity on high-fat diet

  • Cell lines with CRISPR/Cas9-mediated knockout or knockdown can be generated

• Diet-Induced Models:

  • High-fat diet feeding in wild-type vs. Slc16a13 knockout mice reveals protective effects of Slc16a13 deletion

  • Combines genetic manipulation with environmental factors relevant to human disease

• Primary Cell Models:

  • Primary hepatocytes from wild-type or knockout mice

  • Human primary hepatocytes with siRNA knockdown of SLC16A13

  • Studies have shown that disruption of SLC16A13 in primary human hepatocytes leads to changes in fatty acid and lipid metabolism

• Expression Systems:

  • Heterologous expression of SLC16A13 variants in cell lines

  • Can be used to study transport activity and effects of genetic variants

  • Useful for structure-function analyses

• Human Genetic Studies:

  • Research using samples from individuals with T2D risk haplotypes

  • Allelic expression imbalance studies in heterozygous individuals have revealed cis-effects of risk variants

  • Expression quantitative trait loci (eQTL) analyses in human liver samples

These models provide complementary approaches to study SLC16A13 function across different biological systems and disease states.

How can researchers effectively measure changes in SLC16A13 expression and localization in disease states?

To assess SLC16A13 expression and localization changes:

• Transcript Level Analysis:

  • Quantitative RT-PCR using validated primers

  • RNA-seq for comprehensive transcriptomic profiling

  • Digital droplet PCR (ddPCR) for absolute quantification

  • Allele-specific expression analysis in heterozygous samples to detect cis-regulatory effects

• Protein Level Analysis:

  • Western blot using validated antibodies (e.g., 30466-1-AP, PA5-36464)

  • ELISA for quantitative measurement

  • Proteomics approaches for unbiased analysis

• Tissue Distribution Analysis:

  • Immunohistochemistry on tissue sections (liver, pancreas)

  • In situ hybridization for mRNA localization

  • Single-cell RNA-seq for cell type-specific expression patterns

• Subcellular Localization:

  • Immunofluorescence microscopy with cellular compartment markers

  • Cell surface biotinylation assays to quantify plasma membrane expression

  • Subcellular fractionation followed by Western blot

  • Research has shown that coding variants can affect cellular localization by altering protein interactions

• Transport Activity:

  • Radioactive or fluorescent substrate uptake assays

  • Live-cell imaging with fluorescent substrate analogs

  • Electrophysiological measurements in expression systems

• Disease State Comparisons:

  • Compare healthy vs. diseased tissues (e.g., normal liver vs. fatty liver)

  • Nutritional interventions (fasting, high-fat feeding)

  • Pharmacological manipulations relevant to metabolic pathways

These approaches provide comprehensive assessment of both quantitative changes in expression and qualitative changes in localization and function.

How do genetic variants in SLC16A13 affect antibody recognition and experimental outcomes?

Genetic variants in SLC16A13 can impact antibody studies in several ways:

• Epitope Alterations:

  • Coding variants, particularly missense mutations, may alter antibody epitopes

  • The T2D risk haplotype includes four missense mutations in SLC16A11, and similar variants might exist in SLC16A13

  • Researchers should choose antibodies targeting conserved regions when studying variants

  • Alternatively, use multiple antibodies targeting different epitopes to ensure detection

• Expression Level Changes:

  • Non-coding variants may affect expression levels

  • Research has shown cis-regulatory effects of the T2D risk haplotype leading to 62% lower expression from the risk allele

  • Calibrate antibody concentrations accordingly when studying samples with known expression differences

• Protein Stability and Degradation:

  • Some variants may affect protein folding or stability

  • This can lead to altered detection by antibodies despite normal mRNA levels

  • Include controls to assess protein degradation

• Post-translational Modifications:

  • Variants may create or eliminate sites for post-translational modifications

  • This can affect antibody recognition or apparent molecular weight

  • Use phospho-specific or modification-specific antibodies when relevant

• Subcellular Localization:

  • Variants affecting trafficking may alter apparent expression in certain compartments

  • Use both total protein and subcellular fraction analyses

  • Research on SLC16A11 showed coding variants affected interaction with BSG, leading to reduced levels at the cell surface

When studying populations with known SLC16A13 variants, researchers should validate antibody performance in samples with different genotypes.

What are the most effective approaches for studying SLC16A13 transport activity and substrate specificity?

For characterizing SLC16A13 transport function:

• Substrate Transport Assays:

  • Radioactive substrate uptake in cells expressing SLC16A13

  • Fluorescent substrate analogs with live-cell imaging

  • pH-sensitive dyes to measure proton co-transport

  • Research has validated SLC16A13 as a lactate transporter

• Expression Systems:

  • Heterologous expression in Xenopus oocytes for electrophysiology

  • Mammalian cell lines with low endogenous SLC16A13 expression

  • Reconstitution in proteoliposomes for direct transport measurements

• Substrate Specificity Profiling:

  • Competition assays with known substrates of MCT family

  • Radioactive flux studies with various monocarboxylates

  • Structure-activity relationship analysis

  • Focus on monocarboxylates like lactate and pyruvate as likely substrates

• Kinetic Analysis:

  • Determination of Km and Vmax for various substrates

  • pH dependence of transport activity

  • Effects of inhibitors and competing substrates

• Structure-Function Analysis:

  • Site-directed mutagenesis of key residues (e.g., K38, D309, R313 identified in related transporters)

  • Chimeric proteins with other SLC16 family members

  • Truncation and deletion constructs to map functional domains

• Metabolic Tracing:

  • Isotope-labeled substrate tracing in cells with/without SLC16A13

  • Metabolomics profiling to identify accumulated or depleted metabolites

  • In vivo substrate administration to wild-type and knockout animals

These approaches can establish the transport properties of SLC16A13 and its potential role in metabolic regulation.

How can researchers integrate SLC16A13 findings with broader metabolic pathway analyses?

To place SLC16A13 research in broader metabolic context:

• Multi-omics Integration:

  • Combine transcriptomics, proteomics, and metabolomics data

  • Correlate SLC16A13 expression with metabolic pathway activities

  • Identify co-regulated genes and metabolites

• Metabolic Flux Analysis:

  • Use 13C-labeled substrates to trace metabolic pathways

  • Compare flux patterns in presence/absence of SLC16A13

  • Research shows Slc16a13 knockout affects mitochondrial respiration

• Network Analysis:

  • Place SLC16A13 in the context of metabolic and signaling networks

  • Identify hub proteins or pathways connected to SLC16A13 function

  • Use pathway enrichment analysis on differential expression data

• Integrative Physiology:

  • Connect cellular findings to tissue and organism-level physiology

  • Study cross-talk between liver, muscle, adipose tissue

  • Examine effects on systemic glucose and lipid homeostasis

• Mechanism Validation:

  • Test the proposed mechanism where reduced intrahepatocellular lactate drives:

    • AMPK activation

    • Mitochondrial respiration

    • Reduced hepatic lipid content

    • Improved insulin sensitivity

  • Validate each step in the pathway using specific inhibitors or genetic approaches

• Therapeutic Target Assessment:

  • Evaluate SLC16A13 as a drug target for T2D and NAFLD

  • Develop screening assays for SLC16A13 inhibitors

  • Assess specificity within the SLC16 family

  • Model potential metabolic consequences of inhibition

This integrated approach contextualizes SLC16A13 function within the broader metabolic landscape and provides insights into its potential as a therapeutic target.